Raltegravir versus efavirenz in antiretroviral-naive pregnant women living with HIV (NICHD P1081): an open-label, randomised, controlled, phase 4 trial

Study (n=408) reported proportion of patients with viral load <200 copies/ml at or near delivery was significantly greater in raltegravir than efavirenz group (94% vs 84%,; p=0.0015). Severe or life-threatening adverse events were similar in mothers and infants with no deaths.

SPS commentary:

The authors note that their findings support major guidelines. The current preferred integrase inhibitor for the prevention of perinatal HIV transmission is dolutegravir, with raltegravir recommended as an alternative.

The Lancet HIV